Monoclonal antibodies (mAbs) are now established as targeted therapies for malignancies,
transplant rejection, autoimmune and infectious diseases, as well as a range of new …

Cancer treatment today employs a combination of chemotherapy, radiotherapy, and surgery
to prolong life and provide cure. However, many of these treatments can cause …

Background—Because cancer patients survive longer, the impact of cardiotoxicity
associated with the use of cancer treatments escalates. The present study investigates …

Importance Primary analysis of the TRAIN-2 study showed high pathologic complete
response rates after neoadjuvant chemotherapy with or without anthracyclines plus …

Purpose Treatment of breast cancer with trastuzumab is complicated by cardiotoxicity in up
to 34% of the patients. In most patients, trastuzumab-induced cardiotoxicity (TIC) is …

Objectives: This study sought to evaluate the hypothesis that global longitudinal strain (GLS)
guidance of cardioprotective therapy would improve cardiac function of at-risk patients …

Trastuzumab (Trz) is a monoclonal antibody against the human epidermal growth factor
receptor 2 that is found to be overexpressed in 25% to 30% of breast cancer patients. In …

Recent advances in genomics, proteomics, bioinformatics and systems biology have
unraveled the complex aberrant signaling networks in cancer. The knowledge accrued has …

Background Human epidermal growth factor receptor2 (Her2) positive breast cancer
represents 25% of breast cancer cases. Targeted therapy with Her2 monoclonal antibody …

Cardiotoxicity is a common complication of many anti-cancer agents and it remains a major
limitation, strongly impacting the quality of life and the overall survival, regardless of the …